AllSight
Companies · ASTH · Services-Management Consulting Services · Company update · Aug 6, 2026

Profitability beat expectations and lifted the 2026 EBITDA floor

Astrana Health, Inc. (ASTH) — what happened, in plain English, and what it means versus what the market expected.

The quarter was better on earnings than on revenue. Published consensus called for roughly $0.34 of EPS and $985.6 million of revenue; Astrana delivered $0.40 of diluted GAAP EPS and $972.5 million of revenue. That is a modest EPS beat but a roughly 1% revenue shortfall versus the published estimate.

MetricQ2 2026Q2 2025 / expectation
Revenue$972.5M$654.8M; published expectation $985.6M
Diluted GAAP EPS$0.40$0.19; consensus $0.34
Adjusted EPS$0.80$0.55
Adjusted EBITDA$68.9M$48.1M; prior company guide $65M-$70M
Free cash flow, six months$92.9M$103.0M

Underlying profitability clearly outperformed the standing company bar. Adjusted EBITDA rose 43% year over year to $68.9 million, landing above the midpoint of the prior $65 million-$70 million quarterly guide, while adjusted EPS increased to $0.80 from $0.55. Revenue grew 49% to $972.5 million, but the adjusted EBITDA margin remained approximately 7%, so the earnings upside came more from scale and operating execution than from a major margin expansion. (Summary of Selected Financial Results; Reconciliation of Net Income to EBITDA and Adjusted EBITDA)

Management raised the quality of the full-year outlook, but not the growth top line. Full-year revenue guidance stayed at $3.8 billion-$4.1 billion and free-cash-flow guidance stayed at $105 million-$132.5 million. Adjusted EBITDA guidance moved from $250 million-$280 million to $255 million-$280 million, lifting only the low end by $5 million rather than raising the ceiling. That is a constructive revision, but it signals incremental confidence rather than a wholesale reset. (Guidance; Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA)

Cash generation was the main softer spot. Six-month operating cash flow fell to $100.8 million from $107.5 million, and free cash flow declined to $92.9 million from $103.0 million despite much higher earnings. Cash also fell to $400.8 million from $429.5 million at year-end, although debt repayment reduced long-term debt by roughly $102 million. The filing attributes no single definitive cause for the cash-flow decline, so the earnings beat does not yet translate into stronger year-to-date cash conversion. (Cash Flow statement; Balance Sheet Highlights)

Net read: a real but not dramatic positive surprise. The market received a modest GAAP EPS beat, an adjusted-earnings beat against the prior operating guide, and a higher EBITDA guidance floor. Those positives outweigh the small revenue miss and weaker cash conversion, while the unchanged revenue and free-cash-flow outlook limits how much the filing changes the broader 2026 picture.

Read the original 8-K on SEC EDGAR ↗
More from Astrana Health, Inc. (ASTH)
Sep 23, 2026Astrana Health discloses material cyber incident with potential patient-data exposureSep 23, 2026Astrana Health reiterates raised EBITDA outlook as AI platform story takes center stageSep 15, 2026Astrana Health expands AI platform pitch as EBITDA guidance raise loses surpriseAll ASTH filings, decoded →
Related companies in Services-Management Consulting Services
Latest across the market
ACNAccenture earnings beat as Q4 revenue clears guidance, but FY27 growth stays measuredROPRoper Technologies adds NTT DATA CEO to board, but brings no operating changeIIPRIIPR loan increase funds Alewife buildout, but locks in 14% debtGLUEMonte Rosa GFORCE-1 results clear safety bar, but ASCVD Phase 2 moves to 2027SMASmartStop dividend holds at $1.60 annualized as October payout repeats patternHBNCHorizon Bancorp schedules Q3 earnings, offering no fresh business readBrowse all companies, decoded →
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.
Analysis by AllSight · Editorial standards & method · Contact